Scarica l'app Stockscreener
17.38
0.46%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.46
Aprire:
$17.2
Volume 24 ore:
996.82K
Relative Volume:
0.37
Capitalizzazione di mercato:
$2.23B
Reddito:
$745.97M
Utile/perdita netta:
$-99.21M
Rapporto P/E:
-22.49
EPS:
-0.7729
Flusso di cassa netto:
$-5.09M
1 W Prestazione:
-3.71%
1M Prestazione:
+6.69%
6M Prestazione:
+90.99%
1 anno Prestazione:
+115.63%
Intervallo 1D:
$16.86
$17.47
Intervallo di 1 settimana:
$16.86
$18.18
Portata 52W:
$7.065
$19.76
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, NTRA, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
17.38 | 2.12B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
613.78 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
207.66 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.18 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
267.77 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.86 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-29 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
NeoGenomics (NASDAQ:NEO) Healthcare Innovation Gains Attention - Kalkine Media
NeoGenomics (NASDAQ:NEO) Reaches New 12-Month HighHere's Why - MarketBeat
Neogenomics stock hits 52-week high at 16.93 USD - Investing.com
Neogenomics stock hits 52-week high at 16.93 USD By Investing.com - Investing.com India
NeoGenomics, Inc. Revenue Breakdown – NASDAQ:NEO - TradingView
NeoGenomics (NEO) Advances 1.44% to $16.17 as Buyers Hold Above Key SupportPercent Above MA - vinanet.vn
NeoGenomics (NASDAQ:NEO) Enters A New Growth Spotlight - Kalkine Media
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Neogenomics Stock Price Forecast. Should You Buy NEO? - StockInvest.us
NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens - Stock Titan
NeoGenomics | SCHEDULE 13G/A: Others - Moomoo
California State Teachers Retirement System Raises Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. (NEO) Stock Forecasts - Yahoo Finance
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding - simplywall.st
GC To Depart Cancer Diagnostic Co. NeoGenomics - Law360
Renaissance Technologies LLC Acquires New Shares in NeoGenomics, Inc. $NEO - MarketBeat
Form 8K NeoGenomics Inc For: 11 August By Investing.com - Investing.com India
Technical Reactions to NEO Trends in Macro Strategies - Stock Traders Daily
NeoGenomics announces planned departure of General Counsel Alicia Olivo - Investing.com
NeoGenomics (NEO) Slips to $16.50 as Biotech Diagnostic Stocks Face Cautious TradingVWAP Deviation - Vinanet
NeoGenomics (NASDAQ:NEO) Sets New 1-Year HighShould You Buy? - MarketBeat
MFG Wealth Management Inc. Takes Position in NeoGenomics, Inc. $NEO - marketbeat.com
NeoGenomics, Inc. (NEO) Stock forecasts - Yahoo Finance Australia
Has NeoGenomics (NEO) Priced In Its Turnaround Following Q2 Profitability? - simplywall.st
NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed? - finance.yahoo.com
Neogenomics stock hits 52-week high at 16.46 USD By Investing.com - Investing.com UK
Neogenomics stock hits 52-week high at 16.46 USD - Investing.com
NEOUSD (NEOUSD) Stock News Today - TradingKey
NeoGenomics Appoints Carolyn Starrett to its Board of Directors - The National Law Review
NeoGenomics, Inc. $NEO Stock Position Raised by Sei Investments Co. - MarketBeat
Dimensional Fund Advisors LP Buys 225,588 Shares of NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. Revenue Breakdown – BX:NG9 - TradingView
NeoGenomics Laboratories Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Neogenomics Insider Sold Shares Worth $321,400, According to a Recent SEC Filing - marketscreener.com
NeoGenomics (NEO) accounting chief sells 20,000 shares, keeps equity awards - Stock Titan
BlackRock, Inc. Expands NeoGenomics Inc (NEO) Stake with Strategic Share Acquisition - GuruFocus
NeoGenomics Shareholder Action Reminder - TMX Newsfile
NeoGenomics, Inc. $NEO Shares Sold by Glenmede Trust Co. NA - MarketBeat
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
NeoGenomics (NASDAQ:NEO) Reaches New 1-Year HighHere's What Happened - MarketBeat
NEO (NEO) holder to sell 20,000 shares after restricted stock vests - Stock Titan
NEO5107997 Bond Profile — Key Metrics - TradingView
Segall Bryant & Hamill LLC Lowers Holdings in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics (NEO) Following Q2 Profit And Raised Outlook, Is Fair Value Already Priced In? - Yahoo Finance
Is NeoGenomics Inc (NEO) a Bargain After 3.7% Drop? GF Value Says Undervalued - GuruFocus
Trading the Move, Not the Narrative: (NEO) Edition - Stock Traders Daily
Planned insider share sale for NEO (NASDAQ: NEO) under Rule 144 - Stock Titan
Update: NeoGenomics Shares Rise After Q2 Beat - Moomoo
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $19 to $19 - moomoo.com
Neogenomics stock hits 52-week high at 15.61 USD By Investing.com - Investing.com Nigeria
Needham Raises Price Target on NeoGenomics to $19 From $15, Keeps Buy Rating - marketscreener.com
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neogenomics Inc Azioni (NEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Aunan Greg D | Chief Accounting Officer |
Aug 04 '26 |
Sale |
16.07 |
20,000 |
321,400 |
5,153 |
1.39%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):